Upgrade to SI Premium - Free Trial

EU panel recommends approval of Corcept's relacorilant for ovarian cancer

September 18, 2026 8:00 AM
Corcept Therapeutics (NASDAQ: CORT) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA